Aim: To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders.
Material And Methods: Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clinically and with HDRS, CGI and Spilberger scales. Tolerability was evaluated using the UKU scale. Stroop test and verbal fluency test were used. Quality of life was assessed with the SF-36.
Results: The positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS. The combined treatment decreased the level of undesirable side-effects of phenazepam (attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference and orthostatism) during the course of treatment and after the tranquilizer withdrawal. Taken together, the therapeutic efficacy and reduction of side-effects had a positive impact on the quality-of-life of the patients treated with selank as add-on to phenazepam.
Conclusion: The results extend therapeutic possibilities of treatment of anxietyspectrum disorders with the combination of benzodiazepine tranquilizers and selank.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro20151156133-40 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Recovery of consciousness under therapy with benzodiazepines. A case report and literature review].
Zh Vopr Neirokhir Im N N Burdenko
June 2024
Burdenko Neurosurgical Center, Moscow, Russia.
Background: Treatment of patients with prolonged and permanent disturbance of consciousness is still an extremely difficult problem. Nowadays, management is based on pathophysiological and molecular mechanisms of impaired consciousness. Several electrophysiological and pharmacological methods were proposed to restore consciousness in appropriate patients.
View Article and Find Full Text PDFIdentification of clobromazolam in Australian emergency department intoxications using data-independent high-resolution mass spectrometry and the HighResNPS.com database.
J Anal Toxicol
June 2024
Department of Toxicology, Victorian Institute of Forensic Medicine, 65 Kavanagh Street, Southbank, VIC 3006, Australia.
The proliferation of novel psychoactive substances (NPSs) continues to challenge toxicology laboratories. In particular, the United Nations Office on Drugs and Crime considers designer benzodiazepines to be a current primary threat among all NPSs. Herein, we report detection of a new emerging designer benzodiazepine, clobromazolam, using high-resolution mass spectrometry and untargeted data acquisition in combination with a "suspect screening" method built from the crowd-sourced HighResNPS.
View Article and Find Full Text PDFOver several months, 14 people were admitted in 6 hospitals with severe symptoms of intoxication with psychoactive substances as a result of mass poisoning. All symptoms occurred after taking a drink that contained crushed phenazepam tablets. Samples of blood (=10) and urine (=6) taken from 14 sufferers for forensic, chemical and toxicological examination were analyzed using the HPLC-MS/MS method.
View Article and Find Full Text PDFCharacteristics and time course of benzodiazepine-type new psychoactive substance detections in Australia: results from the Emerging Drugs Network of Australia - Victoria project 2020-2022.
Int J Drug Policy
December 2023
Monash University, Department of Forensic Medicine, Southbank, Victoria, Australia; Victorian Institute of Forensic Medicine, Toxicology Department, Southbank, Victoria, Australia; Monash University, Monash Addiction Research Centre, Frankston, Victoria, Australia.
Introduction: The emergence of benzodiazepine-type new psychoactive substances (NPSs) are a growing international public health concern, with increasing detections in drug seizures and clinical and coronial casework. This study describes the patterns and nature of benzodiazepine-type NPS detections extracted from the Emerging Drugs Network of Australia - Victoria (EDNAV) project, to better characterise benzodiazepine-type NPS exposures within an Australian context.
Methods: EDNAV is a state-wide illicit drug toxicosurveillance project collecting data from patients presenting to an emergency department with illicit drug-related toxicity.
Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder.
Psychopharmacol Bull
November 2021
Zastrozhin, M.D., PhD, Head of Laboratory of Genetics and Fundamental Studies, Associate Professor of Addiction Psychiatry Department, Bryun, M.D., PhD, Professor, President, Head of Addiction Psychiatry Department, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia. Efimova, M.D., Physician of Clinical Department, Balashikha Regional Hospital. Skryabin, M.D., Head of Clinical Department, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation. Smirnov, PhD, Associate Professor of Pharmaceutical Toxicology Department, Head of Laboratory of Pharmacokinetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation; NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation. Petukhov, M.D., PhD, Clinical Laboratory Diagnostician of the Analytical Toxicology lab of the Reference Center for Psychoactive Substances use Monitoring, Associate Professor of Pharmaceutical and Toxicological Chemistry, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. Pankratenko, Paramedic-Laboratory Assistant of the Analytical Toxicology Lab of the Reference Center for Psychoactive Substances use Monitoring, Pozdniakov, Researcher of the Laboratory of Genetics and Fundamental Studies, M.D., the Researcher of the Department of Dermatovenerology and Cosmetology, M.D., PhD, Associate Professor of Addiction Psychiatry Department, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation. Kaverina, M.D., PhD, Associate Professor of the Department of Public Health, Healthcare and Hygiene, Peoples Friendship University of Russia, Moscow, Russian Federation, Peoples Friendship University of Russia. Klepikov, M.D., Assistant Professor of Clinical Pharmacology, Kazakh National Medical University, Almaty, Kazakhstan. Grishina, PhD, Head of Biomolecular Researchers Department of the Research Center, Ryzhikova, Research Fellow of the Biomolecular Researchers Department of the Research Center, Bure, PhD, Research Fellow of the Biomolecular Researchers Department of the Research Center, Sychev, Corresponding Member of the Academy of Sciences of Russia, M.D., PhD, Professor, Rector, Head of Clinical Pharmacology and Therapy Department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
Introduction: Phenazepam is commonly administered to patients diagnosed with major depressive disorder. Some proportion of such patients do not show adequate response to treatment regimen containing phenazepam, whereas many of them experience type A adverse drug reactions. Previous studies showed that CYP2D6 IS involved in the biotransformation of phenazepam, the activity of which is highly dependent on the polymorphism of the gene encoding it.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!